Bluebird Bio Files US Application For β-thalassemia Gene Therapy

• Bluebird Bio Inc (NASDAQ: BLUE) completed the rolling submission of its marketing application to the FDA seeking approval for betibeglogene autotemcel (beti-cel) gene therapy.

• The application covers adult, adolescent, and pediatric patients with β-thalassemia who require regular red blood cell (RBC) transfusions across all genotypes.

• Read Next: Bluebird Bio's Shares Drop To 52-Week Low After Another Gene Therapy Trial Placed On FDA Hold.

• The FDA previously granted beti-cel Orphan Drug status and Breakthrough Therapy designation for transfusion-dependent β-thalassemia (TDT).

• If approved, beti-cel will be the first hematopoietic (blood) stem cell (HSC) ex-vivo gene therapy for patients in the U.S.

• The submission is based on data from Phase 3 HGB-207 (Northstar-2) and HGB-212 (Northstar-3) studies and the Phase 1/2 HGB-204 (Northstar) and HGB-205 studies.

• Together, these studies represent more than 220 patient-years of experience with beti-cel.

• The data include two patients with up to seven years of follow-up, eight with at least six years of follow-up, and 19 with at least five years of follow-up.

• Related content: Benzinga's Full FDA Calendar.

• Price Action: BLUE stock gained 5.61% at $19 in premarket trading on the last check Wednesday.

See more from Benzinga

• Click here for options trades from Benzinga

• Fast Track Status Expanded For Inventiva's NASH Treatment

• FDA Not In Favor Of Summit Therapeutics' Endpoint Change To Pivotal Infection Trials

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.